David Michael Nanus

Interim Chief, Division of Hematology and Medical Oncology · Weill Cornell Medicine

Credentials: · · ·

History

division of Hematology and Medical Oncology · Weill Cornell Medicine
Present
NewYork-Presbyterian Hospital - Weill Cornell Medicine Healthcare Systems Cancer Program
Present
Weill Cornell Medicine
1998–Present

Integrative clinical genomics of advanced prostate cancer
Cell · 2015 · 2,800 citations
Renal-cell carcinoma
Review · New England Journal of Medicine · 1996 · Last of 3 authors · 1,460 citations
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Nature Medicine · 2016 · 1,436 citations

Neutral Endopeptidase Inactivation in Advanced Prostate
National Cancer Institute · R01
Contact PI · $2.5M · Weill Medical Coll of Cornell Univ
1998–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $65.7K · Weill Medical Coll of Cornell Univ
2004–2007
Modulation of Retinoic Acid Action in Renal Cancer
National Cancer Institute · R01
Contact PI · $1.8M · Weill Medical Coll of Cornell Univ
2001–2007
Anti Tumor Therapies for Genioturinary Malignancies
National Cancer Institute · K24
Contact PI · $623.5K · Weill Medical Coll of Cornell Univ
2000–2005

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Recruiting · Phase 1
Weill Medical College of Cornell University
2023–2029
Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
Principal investigator · Active not recruiting
Weill Medical College of Cornell University
2022–2027
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Principal investigator · Terminated · Phase 2
Weill Medical College of Cornell University
2021–2025
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2006–2014